Download PDF Johnson & Johnson and its Competitors Johnson & Johnson (J&J) [NYSE: JNJ] is a US-based multinational healthcare corporation operating along its two segments Innovative Medicine and MedTech. Today (as of April 18th, 2024), the firm has a market capitalization of $351.2bn. In 2023, J&J recorded revenues of $85.2bn, Read more…
Download PDF Introduction On October 3rd, pharmaceutical giant Eli Lilly and Company [LLY:NYSE] announced its plans to strengthen its collection of cancer drugs through the acquisition of POINT Biopharma [PNT:NASDAQ] for $1.4bn, representing a premium of almost 90%. The firm’s purchase of POINT, a clinical-stage radiopharmaceutical company with a focus Read more…
Download PDF Illumina, Inc. (ILMN: NASDAQ) – market cap 01/10/2020: $45.5bn Grail – privately held Introduction On September 21st, 2020, the biotech pioneer Illumina agreed to buy the cancer screening start-up Grail in a $8bn deal. Illumina will pay $3.5bn in cash and $4.5bn in common stock to finance Read more…
Download as PDF BSIC has brought you some of the most interesting deals over the last week, we hope you’ll enjoy! Elliot Management builds a 4% stake in Twitter Deal Value: $1bn | Deal Type: Shareholder Activism | Date: 01-Mar-2020 | Nationality: US | Sector: Technology Paul Singer has succeeded in building a stake in Twitter worth more Read more…
Siemens AG (ETR: SIE) – market cap as of 06/04/2018: €88.8bn Siemens Healthineers AG (ETR: SHL) – market cap as of 06/04/2018: €33.9bn Introduction On March 16, 2018, the German conglomerate Siemens performed an initial public offering of its principal and second most profitable division, Healthineers, on the Frankfurt Stock Read more…
Introduction In January 2018, M&A activity surpassed investors’ expectations. According to a report by law firm Baker McKenzie, global mergers and acquisitions are expected to hit an 18-year record, reaching $3.2 trillion in 2018. To the same extent, cross-border M&A is expected to reach new time highs. In the December Read more…
Kite Pharma (NASDAQ:KITE) – Market cap as of 23/09/2017: $10.28bn Gilead Sciences (NASDAQ:GILD) – Market cap as of 23/09/2017: $108.74bn Introduction On August 28, 2017, Gilead Sciences, Inc. and Kite Pharma, Inc. announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for Read more…
Blackstone Group LP; market cap (as of 10/10/15): $39.6bn BioMed Realty Trust Inc; market cap (as of 10/10/15): $4.8bn The Deal in Brief On Thursday Blackstone Group LP agreed to buy landlord BioMed Realty Trust Inc, a supplier of office space to healthcare and biotech companies. This represents an Read more…
Alexion Pharmaceuticals Inc.; market cap (as of 09/05/2015): $32.54bn Synageva Biopharma Corp.; market cap (as of 09/05/2015): $7.91bn Introduction On May 6, 2015, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), the manufacturer of the world’s single most expensive prescription drug Soliris, and Synageva BioPharma Corp. (NASDAQ:GEVA) have entered into a definitive agreement Read more…
AbbVie Inc., Market Cap (as of 19/09/2014): $94.63bn Shire plc., Market Cap (as of 19/09/2014): £31.12bn In its attempt to become one of the global leaders in the rare diseases market, AbbVie successfully got the approval from Shire’s board of directors for its $54bn acquisition. This approval came after two Read more…
Thermo Fisher Scientific Inc. Market Cap(as of 19/04/13) : $28.7 bn Life Technologies Corp. Market Cap(as of 19/04/13): $12.6 bn Deal size: $13.6bn On April 15th , Thermo Fisher Scientific, the second-biggest maker of life sciences equipment by market value, agreed to buy for $13.6bn Life Technologies Corporation, a Read more…
Abbott has endured a strong rally that took out $35 level, leaving the stock set to benefit from the momentum that is being built up following the positive Q1 results. The overall sector is becoming more popular in the screens of traders as Life Technologies Corp. it is set to Read more…
Elan Corporation PLC – Market Cap (as of 01/03/13) : $6.7bn Royalty Management, LLC On Monday, 25 February 2013, Royalty Pharma, the American private equity firm investing in acquiring drug royalties, made an indicative offer to acquire all the outstanding shares of Elan Corporation, the Irish biotech company listed in Read more…